B-cell reduction using cd37-specific and cd20-specific binding molecules

• 收藏
• 分享

专利权人:

EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC

发明人:

JEFFREY A. LEDBETTER,MARTHA SUSAN HAYDEN-LEDBETTER,WILLIAM BRADY,PETER ARMSTRONG THOMPSON,SANDY ALEXANDER SIMON,LAURA SUE GROSMAIRE

申请号：

NZ60629406

公开号：

NZ606294A

申请日:

2006.07.25

申请国别(地区):

NZ

年份:

2014

代理人:

摘要：

Disclosed is the use of one or more CD37-specific binding proteins in the manufacture of a composition for treating a disease or disorder associated with aberrant B cell activity, wherein the composition is to be administered in combination with rituximab.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/